Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal PRKAR2A Primary Antibody for WB - ABIN519185
Uys, Ramburan, Loos, Kinnear, Korkie, Mouton, Riedemann, Moolman-Smook: Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein C. in BMC cell biology 2011
PGD2 (show PTGDS Antibodies)-DP1 (show REEP5 Antibodies) axis-induced M2 polarization facilitates resolution of inflammation through the PRKAR2A-mediated suppression of JAK2 (show JAK2 Antibodies)/STAT1 (show STAT1 Antibodies) signaling.
Results show that mouse Prkar1a (show PRKAR1A Antibodies) and human PRKAR2A exhibited a dynamic spatio-temporal expression in tooth development, whereas neither human PRKAR1A (show PRKAR1A Antibodies) nor mouse Prkar2a showed their expression in odontogenesis.
Results indicte that Cypher/ZASP (show LDB3 Antibodies) interacted with the regulatory subunit RIIalpha of PKA.
a key role for AKAP (show AKAP1 Antibodies)-targeted PKA in control of heart rate and contractile function
The RII alpha regulatory subunit of protein kinase A is not required for normal T cell development, homeostasis, and the generation of a cell-mediated immune response in vivo.
The high-resolution crystal structures of the docking and dimerization (D/D) domain of the RIIalpha regulatory subunit of PKA in complex with the high-affinity anchoring peptide AKAP (show AKAP1 Antibodies)-IS explain the molecular basis for AKAP (show AKAP1 Antibodies)-regulatory subunit recognition.
crystal structure of RIIalpha holoenzyme solved and compared to the RIalpha (show PRKAR1A Antibodies) holoenzyme; structure demonstrates the conserved and isoform-specific features of RI and RII and the importance of ATP
AKAP121 (show AKAP1 Antibodies) and PKAR2A serve to enhance steroidogenesis by directing the synthesis and activation of STAR at the mitochondria in response to cAMP.
protein kinase cAMP dependent regulatory type II alpha showed a clear-cut double striation pattern on each m-line and z-line.
High PK-R2 (show PROKR2 Antibodies) expression is associated with colorectal cancer.
Prkar2a deficiency predisposes to hematopoietic malignancies in vivo. RIIalpha's likely association with HS and DLBCL was hitherto unrecognized and may lead to better understanding of these rare neoplasms.
Disruption of Snapin (show SNAPIN Antibodies)-PKR2 (show PROKR2 Antibodies) interaction did not affect PKR2 (show PROKR2 Antibodies) signaling, but increased the ligand-induced degradation, implying a role of Snapin (show SNAPIN Antibodies) in the trafficking of PKR2 (show PROKR2 Antibodies).
we demonstrate that neurochondrin has strong isoform selectivity towards the RIIa subunit of PKA with nanomolar affinity
These data demonstrate that some Kallmann syndrome-associated, intracellularly retained mutant PKR2 (show PROKR2 Antibodies) receptors can be functionally rescued, suggesting a potential treatment strategy for patients bearing such mutations.
while there is no change in type II regulatory (RIIalpha) or catalytic (Calpha (show PRKACA Antibodies)) subunit expression, site specific RIIalpha (Ser96) and Calpha (show PRKACA Antibodies) (Thr197) phosphorylation are increased in heart failure, as well as expression of type I regulatory subunit (RI)
Smad4 (show SMAD4 Antibodies) and the R subunit of the protein kinase A holoenzyme form a functional complex in vivo in response to TGFbeta (show TGFB1 Antibodies).
ETO nervy homology region (NHR) 3 domain-PKA(RIIalpha) protein interaction does not appear to significantly contribute to AML1-ETO's ability to induce leukemia.
These data implicate the involvement of PKA-RIIalpha anchoring apical targeting of distinct proteins and glycosphingolipids to apical plasma membrane domains and suggest that rerouting may underlie the delayed Golgi-to-apical surface transport of MDR1 (show TBC1D9 Antibodies).
angle X-ray scattering studies indicate RIalpha (show PRKAR1A Antibodies), RIIalpha, and RIIbeta (show PRKAR2B Antibodies) homodimers differ markedly in overall shape despite extensive sequence homology and similar molecular masses;cAMP binding does not cause large conformational changes(Prkar1a (show PRKAR1A Antibodies), Prkar2a)
cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. The protein encoded by this gene is one of the regulatory subunits. This subunit can be phosphorylated by the activated catalytic subunit. It may interact with various A-kinase anchoring proteins and determine the subcellular localization of cAMP-dependent protein kinase. This subunit has been shown to regulate protein transport from endosomes to the Golgi apparatus and further to the endoplasmic reticulum (ER).
cAMP-dependent protein kinase regulatory subunit RII alpha
, cAMP-dependent protein kinase type II-alpha regulatory subunit
, protein kinase A, RII-alpha subunit
, cAMP-dependent protein kinase, regulatory subunit alpha 2
, protein kinase, cAMP-dependent, regulatory, type II, alpha
, carnitine/acylcarnitine translocase
, cAMP-dependent protein kinase type II-alpha regulatory subunit-like
, protein kinase cAMP-dependent regulatory type II alpha
, protein kinase, cAMP-dependent, regulatory, type 2, alpha
, LOW QUALITY PROTEIN: cAMP-dependent protein kinase type II-alpha regulatory subunit